Wuhan Healthgen Biotechnology Corp Class A 688765
SSE · China · Health Technology
CNY 39.84+0.37 (+0.94%)
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
These ratios divide the lines in the statements below by the current price; both inputs of every value are visible on this page. The P/E on the overview comes from the same calculation. P/E and P/S are left blank for loss-making companies or where revenue is not reported. Not investment advice.
| LTM | FY2025 | |
|---|---|---|
| Revenue | CNY 53.43M | CNY 47.86M |
| Revenue growth (YoY) | — | — |
| Cost of Revenue | MakklerPRO | MakklerPRO |
| Gross Profit | MakklerPRO | MakklerPRO |
| Gross margin | MakklerPRO | MakklerPRO |
| Operating expenses | MakklerPRO | MakklerPRO |
| Operating Income | MakklerPRO | MakklerPRO |
| Operating margin | MakklerPRO | MakklerPRO |
| EBITDA | MakklerPRO | MakklerPRO |
| Pre-tax income | MakklerPRO | MakklerPRO |
| Net Income | -CNY 138.17M | -CNY 157.04M |
| Net margin | MakklerPRO | MakklerPRO |
| Diluted EPS | MakklerPRO | MakklerPRO |
| Diluted shares | MakklerPRO | MakklerPRO |
| LTM | FY2025 | |
|---|---|---|
| Cash & equivalents | MakklerPRO | MakklerPRO |
| Total Current Assets | MakklerPRO | MakklerPRO |
| Total Assets | CNY 3.85B | CNY 3.70B |
| Total Current Liabilities | MakklerPRO | MakklerPRO |
| Total Liabilities | MakklerPRO | MakklerPRO |
| Total debt | MakklerPRO | MakklerPRO |
| Total Equity | MakklerPRO | MakklerPRO |
| LTM | FY2025 | |
|---|---|---|
| Cash from Operations | -CNY 167.58M | -CNY 128.32M |
| Capital expenditure | MakklerPRO | MakklerPRO |
| Free cash flow | MakklerPRO | MakklerPRO |
| Cash from Investing | MakklerPRO | MakklerPRO |
| Cash from Financing | MakklerPRO | MakklerPRO |
Standardised statements compiled from the company's annual and interim reports. The "LTM" column covers the last four reported quarters; balance-sheet lines in it are from the latest quarter. Lines the company does not report are left blank rather than approximated. Not investment advice.